Literature DB >> 14567033

Carrier solutions for intraperitoneal chemotherapy.

Faheez Mohamed1, Paul H Sugarbaker.   

Abstract

Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration and nonuniform intraperitoneal distribution by the drug-containing solution. A better understanding of the pharmacodynamics of carrier solutions for intraperitoneal chemotherapy may impact on both these problems. Not only is the choice of drug important, but also the matching of the chosen drug to an appropriate carrier solution. It would appear that high molecular weight solutions offer a number of advantages over low molecular weight glucose and saline solutions for chemotherapeutic agents that have a high molecular weight with a slow peritoneal clearance. The use of carrier solutions of varying tonicity requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567033     DOI: 10.1016/s1055-3207(03)00039-5

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  10 in total

1.  Appraisal of peritoneal cavity's capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapy.

Authors:  Alexis Duez; Eddy Cotte; Olivier Glehen; François Cotton; Naoual Bakrin
Journal:  Surg Radiol Anat       Date:  2009-03-19       Impact factor: 1.246

2.  HIPEC Methodology and Regimens: The Need for an Expert Consensus.

Authors:  Aditi Bhatt; Ignace de Hingh; Kurt Van Der Speeten; Martin Hubner; Marcello Deraco; Naoual Bakrin; Laurent Villeneuve; Shigeki Kusamura; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2021-06-17       Impact factor: 5.344

3.  Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer.

Authors:  Paul H Sugarbaker; Kurt Van der Speeten; O Anthony Stuart
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

4.  Hyperthermic intraperitoneal chemotherapy: Rationale and technique.

Authors:  Santiago González-Moreno; Luis A González-Bayón; Gloria Ortega-Pérez
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

5.  Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.

Authors:  Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

6.  Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.

Authors:  Belén Valenzuela; Ricardo Nalda-Molina; Pere Bretcha-Boix; Vanesa Escudero-Ortíz; Maria José Duart; Vicente Carbonell; Manuel Sureda; José Pascual Rebollo; Josep Farré; Antonio Brugarolas; Juan José Pérez-Ruixo
Journal:  AAPS J       Date:  2011-01-06       Impact factor: 4.009

7.  Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats.

Authors:  Zhi-Gang Wei; Guo-Xin Li; Xiang-Cheng Huang; Li Zhen; Jiang Yu; Hai-Jun Deng; Shan-Hua Qing; Ce Zhang
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

Review 8.  Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective.

Authors:  Priya Mistry; Faheez Mohamed; Sanjeev Dayal; Tom D Cecil; Brendan J Moran
Journal:  Eur J Hosp Pharm       Date:  2016-04-05

9.  Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model.

Authors:  Eun Jung Park; Junhyun Ahn; Sang Won Gwak; Kyung Su Park; Seung Hyuk Baik; Sung-Joo Hwang
Journal:  Ann Surg Oncol       Date:  2018-07-18       Impact factor: 5.344

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.